Brucellosis market research report— by species (Brucella suis, B. abortus, B. melitensis), by diagnosis (serological tests, molecular techniques, bone marrow biopsy, CT, MRI), by treatment (vaccine, antibiotics), by end user— Global forecast till 2023

Market Scenario:

Brucellosis is a bacterial infection that spreads from animals to people most often via unpasteurized milk, cheese and other dairy products. More rarely, the bacteria that cause brucellosis can spread through the air or through direct contact with infected animals. The infection can usually be treated successfully with antibiotics. Avoiding unpasteurized dairy products and taking precautions while working with animals or in pathogy laboratories may prevent brucellosis. The global burden of human brucellosis remains enormous as the organism causes more than 500,000 infections per year worldwide. Usually, brucellosis is more common in males than in females and are generally non occurring in infants.

Brucella are small aerobic intracellular organisms which localize in the reproductive organs of host animals, causing abortions and sterility. They usually spread through fluids such as animal’s urine, milk, placental fluid, and others. To this day, 8 species have been identified, named primarily for the source animal or features of infection. Out of these, four species are significantly pathogenous to humans, these include Brucella melitensis (sheep, goats), Brucella suis (swine), Brucella abortus (buffalos, bison), Brucella canis (dogs)

In the U.S., the Nationwide eradication of brucellosis from domestic cattle and bison are carried out by governing bodies such as USDA, APHIS, Cooperative State Federal Program. Currently all 50 states as well as Puerto Rico and the U.S. Virgin Islands are brucellosis free. Any livestock market that has been approved by the State is handled under the supervision of the Cooperative State–Federal Brucellosis Eradication Program.

A Brucella abortus product that is approved by the Brucellosis Eradication Program and licensed under USDA for injection into cattle to enhance their resistance to brucellosis. The brucellosis vaccine is called RB51. Pasteurization has been proven to destroy the causative agent of Brucellosis.

The global market of brucellosis is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.

Intended Audience:

- Brucellosis Vaccine Suppliers
- Brucellosis Drug Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities

Segmentation:

The brucellosis is segmented on the basis of species, diagnosis, treatment and end-users.

On the basis of species, the market is segmented into Brucella suis, Brucella abortus, Brucella
**melitensis, Brucella canis and others**

On the basis of diagnosis, market is segmented into serological tests, molecular techniques, bone marrow biopsy, X-rays, computerized tomography (CT), magnetic resonance imaging (MRI), cerebrospinal fluid culture, echocardiography and others. The serological tests is segmented into serum agglutination test, rose bengal test, lateral flow assay, compliment fixation test, coombs test, enzyme linked immuno sorbent assay/am, and immunocapture-agglutination test (brucellacapt). The molecular techniques is segmented into Polymerase Chain Reaction (PCR), Loop-mediated isothermal amplification assay, Multiple Locus VNTR Analysis (MLVA) typing. The Polymerase Chain Reaction (PCR) is further classified into standard PCR, real time PCR, nested PCR, PCR based assays

On the basis of treatment market is segmented into antibiotics, vaccines, and others

On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.

**Research Methodology**

![Research Methodology](image)

Sources: Annual reports, Press release, White paper, and Company presentation

**Regional Analysis:**

The global brucellosis market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

The European brucellosis market is the largest market owing to the high investment in various private and government funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.

America is projected to hold the second largest share of the global brucellosis market as due to the eradication of these disease from the USA. Currently, fewer than 100 cases are reported annually to the Centers for Disease Control and Prevention (CDC) with approximately 60% of human brucellosis cases in the United States now occur in California and Texas. Brucellosis has become rare in North America due to numerous veterinary control measures such as routine screening and vaccination of domestic livestock. Most cases of brucella infection in the U.S. is due to the consumption of imported unpasteurized dairy products from Mexico.

The Asia Pacific and the Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector. The heaviest disease burden lies in countries of the Mediterranean basin and Arabian Peninsula, and the disease is also common in India, Mexico, and
South & Central America. In Africa, incidence rates of 1.2-70 cases per 100,000 people have been reported. In Africa, such endemic diseases are controlled through animal slaughter due to the fragile nature of the food supply.

**Key Players**

Some of the key players in the global brucellosis market are Hester Biosciences Limited, ATA FEN Inc., Biogénesis-Bagó S.A., Biopharma, Biovet, Calier & Biológicos Laverlam, Merck Animal Health (MSD Animal Health), Colorado Serum Company, Indian Immunologicals Limited, Dollvet, Veterinary Technologies Corporation, China Animal Husbandry Co., Ltd. (CAHIC), LABIOFAM, BCG Vaccine Laboratory, and others.

**Contents:***

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation

Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Brucellosis Market, by Species
6.1 Introduction
6.2 Brucella suis
6.2.1 Market Estimates & Forecast, 2016 – 2023
6.3 Brucella abortus
6.3.1 Market Estimates & Forecast, 2016 – 2023
6.4 Brucella melitensis
6.4.1 Market Estimates & Forecast, 2016 – 2023
6.5 Brucella canis
6.5.1 Market Estimates & Forecast, 2016 – 2023
6.5 Others

Chapter 7. Global Brucellosis Market, by Diagnosis

7.1 Introduction
7.2 Serological tests
7.2.1 Market Estimates & Forecast, 2017 – 2023
7.2.2 Serum agglutination test
7.2.2.1 Market Estimates & Forecast, 2017 – 2023
7.2.3 Rose Bengal test
7.2.3.1 Market Estimates & Forecast, 2017 – 2023
7.2.4 Lateral flow assay
7.2.4.1 Market Estimates & Forecast, 2017 – 2023
7.2.5 Compliment fixation test
7.2.5.1 Market Estimates & Forecast, 2017 – 2023
7.2.6 Coombs test
7.2.6.1 Market Estimates & Forecast, 2017 – 2023
7.2.7 Enzyme linked immuno sorbent assay
7.2.7.1 Market Estimates & Forecast, 2017 – 2023
7.2.8 Immuno capture-agglutination test (brucellacapt)
7.2.8.1 Market Estimates & Forecast, 2017 – 2023
7.3 Molecular techniques
7.3.1 Market Estimates & Forecast, 2017 – 2023
7.3.2 Polymerase Chain Reaction (PCR)
7.3.2.1 Market Estimates & Forecast, 2017 – 2023
7.3.2.2 Standard PCR
7.3.2.2.1 Market Estimates & Forecast, 2017 – 2023
7.3.2.3 Real time PCR
7.3.2.3.1 Market Estimates & Forecast, 2017 – 2023
7.3.2.4 Nested PCR
7.3.2.4.1 Market Estimates & Forecast, 2017 – 2023
7.3.2.5 PCR based assays
7.3.2.5.1 Market Estimates & Forecast, 2017 – 2023
7.3.3 Loop- mediated isothermal amplification assay
7.3.3.1 Market Estimates & Forecast, 2017 – 2023
7.3.4 Multiple Locus VNTR Analysis (MLVA) typing
7.3.4.1 Market Estimates & Forecast, 2017 – 2023
7.4 Bone marrow biopsy
7.4.1 Market Estimates & Forecast, 2017 – 2023
7.5 X-rays
7.5.1 Market Estimates & Forecast, 2017 – 2023
7.6 Computerized tomography (CT)
7.6.1 Market Estimates & Forecast, 2017 – 2023
7.7 Magnetic resonance imaging (MRI)
7.7.1 Market Estimates & Forecast, 2017 – 2023
7.8 Cerebrospinal fluid culture
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments

Chapter 12 Company Profiles
12.1 Hester Biosciences Limited
12.1.1 Company Overview
12.1.2 Treatment Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 ATA FEN Inc.
12.2.1 Company Overview
12.2.2 Treatment Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Biogénesis-Bagó S.A.
12.3.1 Company Overview
12.3.2 Treatment Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Biopharma
12.4.1 Company Overview
12.4.2 Treatment/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Biovet
12.5.1 Company Overview
12.5.2 Treatment Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Calier & Biologicos Laverlam
12.6.1 Company Overview
12.6.2 Treatment Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 Merck Animal Health
12.7.1 Overview
12.7.2 Treatment Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Colorado Serum Company
12.8.1 Company Overview
12.8.2 Treatment/Business Segment Overview
12.8.3 Financial Overview
Chapter 12.8.4 Key Development

Chapter 12.8.5 SWOT Analysis

Chapter 12.9 Indian Immunologicals Limited

Chapter 12.9.1 Company Overview

Chapter 12.9.2 Treatment Overview

Chapter 12.9.3 Financial overview

Chapter 12.9.4 Key Developments

Chapter 12.10 Others

Chapter 13 MRFR Conclusion

Chapter 13.1 Key Findings

Chapter 13.1.1 From CEO’s View Point

Chapter 13.1.2 Unmet Needs of the Market

Chapter 13.2 Key Companies to Watch

Chapter 14 Appendix

List of Tables

Table 1 Brucellosis Industry Synopsis, 2017 – 2023

Table 2 Brucellosis Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Brucellosis Market by Region, 2017 – 2023, (USD Million)

Table 4 Brucellosis Market by Species, 2017 – 2023, (USD Million)

Table 5 Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

Table 6 Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

Table 7 Brucellosis Market by End Users, 2017 – 2023, (USD Million)

Table 8 North America Brucellosis Market by Species, 2017 – 2023, (USD Million)

Table 9 North America Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

Table 10 North America Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

Table 11 North America Brucellosis Market by End User, 2017 – 2023, (USD Million)

Table 12 US Brucellosis Market by Species, 2017 – 2023, (USD Million)

Table 13 US Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

Table 14 US Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

Table 15 US Brucellosis Market by End User, 2017 – 2023, (USD Million)

Table 16 Canada Brucellosis Market by Species, 2017 – 2023, (USD Million)

Table 17 Canada Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

Table 18 Canada Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

Table 19 Canada Brucellosis Market by End User, 2017 – 2023, (USD Million)

Table 20 South America Brucellosis Market by Species, 2017 – 2023, (USD Million)

Table 21 South America Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

Table 22 South America Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

Table 23 South America Brucellosis Market by End User, 2017 – 2023, (USD Million)

Table 24 Europe Brucellosis Market by Species, 2017 – 2023, (USD Million)

Table 25 Europe Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

Table 26 Europe Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

Table 27 Europe Brucellosis Market by End User, 2017 – 2023, (USD Million)

Table 28 Western Europe Brucellosis Market by Species, 2017 – 2023, (USD Million)

Table 29 Western Europe Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

Table 30 Western Europe Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

Table 31 Western Europe Brucellosis Market by End User, 2017 – 2023, (USD Million)

Table 32 Eastern Europe Brucellosis Market by Species, 2017 – 2023, (USD Million)
Table 33 Eastern Europe Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 34 Eastern Europe Brucellosis Market by Treatment, 2017 – 2023, (USD Million)
Table 35 Eastern Europe Brucellosis Market by End User, 2017 – 2023, (USD Million)
Table 36 Asia Pacific Brucellosis Market by Species, 2017 – 2023, (USD Million)
Table 37 Asia Pacific Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 38 Asia Pacific Brucellosis Market by Treatment, 2017 – 2023, (USD Million)
Table 39 Asia Pacific Brucellosis Market by End User, 2017 – 2023, (USD Million)
Table 40 The Middle East & Africa Brucellosis Market by Species, 2017 – 2023, (USD Million)
Table 41 The Middle East & Africa Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 42 The Middle East & Africa Brucellosis Market by Treatment, 2017 – 2023, (USD Million)
Table 43 The Middle East & Africa Brucellosis Market by End User, 2017 – 2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Brucellosis Market
Figure 3 Segmentation Market Dynamics for Brucellosis Market
Figure 4 Global Brucellosis Market Share, by Species 2016
Figure 5 Global Brucellosis Market Share, by Diagnosis 2016
Figure 6 Global Brucellosis Market Share, by Treatment, 2016
Figure 7 Global Brucellosis Market Share, by Technology, 2016
Figure 8 Global Brucellosis Market Share, by End Users, 2016
Figure 9 Global Brucellosis Market Share, by Region, 2016
Figure 10 North America Brucellosis Market Share, by Country, 2016
Figure 11 Europe Brucellosis Market Share, by Country, 2016
Figure 12 Asia Pacific Brucellosis Market Share, by Country, 2016
Figure 13 The Middle East & Africa Brucellosis Market Share, by Country, 2016
Figure 14 Global Brucellosis Market: Company Share Analysis, 2016 (%)
Figure 15 Hester Biosciences Limited: Key Financials
Figure 16 Hester Biosciences Limited: Segmental Revenue
Figure 17 Hester Biosciences Limited: Geographical Revenue
Figure 18 ATA FEN Inc.: Key Financials
Figure 19 ATA FEN Inc.: Segmental Revenue
Figure 20 ATA FEN Inc.: Geographical Revenue
Figure 21 Biogénesis-Bagó S.A.: Key Financials
Figure 22 Biogénesis-Bagó S.A.: Segmental Revenue
Figure 23 Biogénesis-Bagó S.A.: Geographical Revenue
Figure 24 Biopharma: Key Financials
Figure 25 Biopharma: Segmental Revenue
Figure 26 Biopharma: Geographical Revenue
Figure 27 Biovet: Key Financials
Figure 28 Biovet: Segmental Revenue
Figure 29 Biovet: Geographical Revenue
Figure 30 Calier & Biologicos Laverlam: Key Financials
Figure 31 Calier & Biologicos Laverlam: Segmental Revenue
Figure 32 Calier & Biologicos Laverlam: Geographical Revenue
Figure 33 Merck Animal Health: Key Financials
Figure 34 Merck Animal Health: Segmental Revenue
Figure 35 Merck Animal Health: Geographical Revenue
Figure 36 Colorado Serum Company: Key Financials